New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness.

Yang, Haitang; Shun-Qing, Liang; Schmid, Ralph A.; Peng, Ren-Wang (2019). New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. Frontiers in oncology, 9, p. 953. Frontiers Research Foundation 10.3389/fonc.2019.00953

[img]
Preview
Text
Yang HAITANG 19 FrontOncol KRAS REVIEW.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (2MB) | Preview

In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, for which, however, there remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS point mutations, varying dependence on mutant KRAS, wide spectrum of other co-occurring genetic alterations, as well as distinct cellular status across the epithelial-to-mesenchymal transition (EMT), has not only deepened our understanding about the pathobiology of KRAS-mutant NSCLC but also brought about unprecedented new hopes for precision treatment of patients. In this review, we provide an update on the most recent advances in KRAS-mutant lung cancer, with a focus on mechanistic insights into tumor heterogeneity, the potential clinic implications and new therapies on horizons tailored for KRAS-mutant lung cancer.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Thoracic Surgery
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Thoraxchirurgie

Graduate School:

Graduate School for Cellular and Biomedical Sciences (GCB)

UniBE Contributor:

Yang, Haitang; Shun-Qing, Liang; Schmid, Ralph and Peng, Ren-Wang

Subjects:

600 Technology > 610 Medicine & health
500 Science > 570 Life sciences; biology

ISSN:

2234-943X

Publisher:

Frontiers Research Foundation

Language:

English

Submitter:

Thomas Michael Marti

Date Deposited:

12 Nov 2019 09:41

Last Modified:

24 Nov 2019 02:44

Publisher DOI:

10.3389/fonc.2019.00953

PubMed ID:

31612108

Uncontrolled Keywords:

KRAS heterogeneity immunotherapy lung cancer mitogen-activated protein kinases targeted therapy

BORIS DOI:

10.7892/boris.134637

URI:

https://boris.unibe.ch/id/eprint/134637

Actions (login required)

Edit item Edit item
Provide Feedback